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The aim of this study was to investigate the different bariatric surgeries relationship with 
pancreatic -cell turnover. We used healthy adult male Wistar rats to undergo the different 
techniques. We developed three surgical techniques (malabsorptive, Sleeve gastrectomy and 
Roux-Y Gastric Bypass-), and two control groups (Sham and fasting control). Pancreatic -cell 
mass was measured, as well as apoptosis, proliferation and neogenesis related to cellular 
turnover. Otherwise, we measured the functional issues to elucidate the physiological role 
that these surgical techniques trigger in the carbohydrate metabolism (e.g. food intake, 
weight gain, intraperitoneal glucose tolerance test, and basal glycaemia). Results included the 
differences that these parameters underwent in each surgical model. The -cell mass 
presented modifications that were related with proliferation processes. We reported 
significant increase of -cell mass in the malabsorptive technique. Other while the peripheral 
resistance to insulin trended to reduce in rats underwent with malabsorptive and mixed 
techniques. The goal of the present study was to present how different bariatric surgical 
techniques affected on pancreatic -cell turnover. We considered that these implications of 
surgery over the endocrine pancreas must be one of the mechanisms related to the 
improvement of type 2 Diabetes mellitus afterward the bariatric surgery. 
  




The remission of type 2 diabetes (T2DM) has been observed as an additional outcome of 
surgical treatment for morbid obesity in humans 1. Induced caloric intake reduction, weight 
loss and malabsorption of carbohydrates and fats were suggested as explanations for this 
effect of bariatric surgery on T2DM 2, 3, 4. More recently, the bile acids, lipoproteins 5 and 
microbiota have been invoked as effectors in this entero-pancreatic axis 6. Many mechanisms 
have been proposed but the mechanism of this success remain unclear.   
The glycaemic control often occurs prior to significant weight loss in surgical patients, and 
even glycaemic homeostasis are independent of the nonsurgical procedures (as gastric band) 
6, 7, 8. Nowadays, it is assumed that glycaemic control might be a direct effect on insulin 
secretion or sensitivity.  
We inferred about the idea that insulin secretion must be related to cellular changes in 
endocrine pancreas. Pancreatic -cells adapt to stress situation, including obesity, pregnancy 
and surgery 9. We believe that improvement of bariatric surgery must be related to changes 
in cellularity of -cell mass, which it is at the basis of changes in insulin secretion. There must 
be some effectors acting as stimuli for these endocrine changes of the pancreas. Probably 
many substances have been implied in this enteral-axis, which finally will be the executers on 
-cell proliferation. 
Several incretins have been signed in this mechanism of stimuli over the pancreatic cellularity. 
GLP-1 or PYY -both secreted by the L-cell in the ileum- or ghrelin in the antrum of the stomach; 
all of which have been involved in physiological 10, 11 and physio-pathological 12, 13 changes in 
the entero-insular axis and -cell mass 14, 15. But not exclusively, since different peptides –GIP, 
leptin or CCK are among those- are already object of studies in this sense 16. 
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However, the study of the relative degree of beta-cell mass changes related to the portions 
and extension of digestive tube implied has not been reported. In this way, many studies 
reported that enhanced delivery of nutrients to the distal intestine and increased secretion of 
hindgut signals might affect the entero-insular axis 17. These explanations could be related to 
the pathophysiological consequences of some techniques (e.g. Roux–Y Gastric bypass, RYGB) 
18, 19, 20, which exercise a massive distortion of the digestion and absorption processes. 
However, this hypothesis does not explain the positive behaviour of restrictive techniques (as 
Sleeve Gastrectomy, SG), which is receiving progressively more attention in the clinic and is 
broadly employed.  
Therefore, we hypothesised that the digestive tube must trigger on the cellularity of the 
endocrine pancreas. All the entero-hormones, which have been related with a complex 
stability of homeostasis named as incretin-anti-incretin balance 21, 22, are involved in the 
reported glycaemic improvement of the T2DM, by the way of increased cell turnover 9, 23, 
24. 
This -cell mass is severely affected in the long-term obesity and T2DM. Many reports showed 
that-cell function is clearly improved after bariatric surgery 9, 25, 26, 27. Around this, the 
purpose of the present study was to know how different bariatric procedures could affect 
pancreatic -cell mass homeostasis. We employed a healthy, non-obese, animal model, the 
Wistar rat, in order to reduce the interferences with concomitant pathologies. 
We included a malabsorptive model by resecting 50% of the small bowel to the usual bariatric 
techniques related to human treatment (RYGB and SG). Thus, IR50 is considered as a purely 
malabsorptive surgical technique. Even though this technique was actually rejected as a 
bariatric surgery, it is included here to complete the sequence of variation related to these 
surgical models.  
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We measured various functional issues to elucidate the carbohydrate metabolism for each 
surgical group. These physiological parameters were triggered as consequences to the surgical 
techniques. We completed a sequence of morphometric parameters to conclude the trend of 
the -cell, which included the measurements of pancreatic -cell mass, apoptosis, 
proliferation and neogenesis. We hypothesised that the -cell mass must be modified after 
bariatric surgery, and this -cell mass modification could partially be in the basis of the T2DM 
clinical amelioration.  
 
 
MATERIAL AND METHODS 
Animals 
All animal procedures were performed with the approval of the University of Cadiz Committee 
for the Ethical Use and Care of Experimental Animals. The 30 male Wistar rats were stabled in 
randomized groups under constant temperature and humidity conditions in a 12-hour 
light/dark cycle, with ad libitum access to normal chow and water. We did not used female 
rats was to avoid the cyclic variations of gonadotropin hormonal effect on the glycaemic 
metabolism. 
Weight gain and feed intake. Basal glycaemia. 
To evaluate the effect of bariatric surgery in animals, we controlled the weight increase of the 
animals, as well as the grams of feed that these animals ingested. The chow intake was 
quantified every two days for the first month after surgery. The weight increase was measured 
every two days for the first month after surgery, and every week for the last two months. 
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Once a week, the basal glycaemia was measured with a glucometer (Glucocard G-Meter 1810, 
Menarini diagnostics, Italy) and expressed as mg of glucose/decilitre of blood. 
Surgical interventions and fasting controls 
The fasting control group (FC) was subjected the same preoperative and postoperative 
conditions as the operated groups, with a 12 hour-fasting pre- and post-surgical period. All 
surgical procedures were performed in anesthetised animals with continuous infusion of 
Isofluorane 3% V/V (Isoflo, Abbott 571329.8). An intake re-adaptation period followed each 
surgery to normalize fasting. 
IR50 as the malabsorptive bariatric surgery was performed in the following steps 28. A 
laparotomy of about 3 cm in the midline of the abdomen. We identified the angle of Treitz 
and the ileocecal valve as anatomical references. The bowel between these points was 
exposed and measured. We made a resection of the central 50%, followed by an end-to-end 
anastomosis with 5-0 monoplane silk suture (polypropylene, Ethicon Prolene), leaving the 
proximal half of the jejunum and the distal half of the digestive tube. So, we did not remove 
the ileum. The ileum in the rat is shortened than in human. This procedure did not affect the 
ileum. Lastly, instillation of physiological saline at 37ºC in abdominal cavity and closure of the 
abdominal wall in one layer was done. These final steps were repeated in every surgical 
procedure. 
The RYGB, mixed -malabsorptive and restrictive- bariatric surgery, involved the exclusion of 
the proximal intestine by the bypass of the duodenum and a part of the jejunum, as well as 
the reduction of stomach to the fore-stomach. The stomach was exposed and we sectioned 
the gastric fundus, while preserving approximately 20% of the original gastric volume. The 
jejunum was dissected at 8 cm from the ligament of Treitz, and the terminal jejunum of the 
section was connected via end-to-end anastomosis to the preserved for fundus. The antro-
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jejunal loop (biliopancreatic loop) was continued with the alimentary loop at 10 cm of the 
fundus-jejunum anastomosis. 
Sleeve Gastrectomy (SG) was performed by a laparotomy of 5 cm in the upper third of the 
abdomen through sectioning of the gastrosplenic ligament and exposing the stomach. A 
curved forceps was applied from the angle of Hiss to antrum, performing a cylindrical stomach 
of approximately 0.5 cm of diameter. The stomach section delimited the section of the most 
fundus, stomach-corpus at greater curvature level, and antrum; the pylorus was preserved. 
The SG reduced the initial stomach volume by approximately 20%. SG reproduced the actual 
selective technique used in humans as the restrictive model of bariatric surgery. 
The Sham-technique (Sham) reproduced the surgical aggression over the digestive tract and 
the stress of both pre-surgery and post-surgery, but maintains the integrity of the digestive 
tube. Sham was performed by an incision of about 3 cm in the middle area of the abdomen, 
exposing the small bowel loops. After we measured the size from the angle of Treitz to 
ileocecal valve, a transversal enterotomy section was performed, without intestinal resection, 
and end-to-end anastomosis. 
Intra-peritoneal glucose tolerance test (IPGTT): 
A blood sample of 0.5 ml was collected from the tail vein of each fasted animal. Then, an 
intraperitoneal injection of 40% solution of glucose was administered (2 gr/Kg body weight) 
followed by blood sampling from the tail vein at 15, 30, 60 and 120 minutes following glucose 
administration. We realized the IPGTT monthly. Basal glycaemia was measured pre-operatory 
and weekly after surgery. Glycaemia was measured with a glucometer (Glucocard G-Meter 
1810, Menarini diagnostics, Italy) and expressed as mg of glucose/decilitre of blood.
-cell mass quantification: 
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Three months after surgical intervention, animals were sacrificed by an intraperitoneal Chloral 
Hydrate overdose and perfused with Bouin’s solution (25% Formalin/75% H2O saturated with 
Picric acid). After this, the pancreas was resected, weighed (precision scale Ohaus Pioneer 
Mod PA 3102), and post-fixed in Bouin’s solution, 24h at 4ºC. The fixed pancreas was 
dehydrated, paraffin embedded and longitudinal 10 m microtome sections were obtained. 
To calculate -cell mass, insulin producing cells were stained using a monoclonal mouse anti-
insulin antibody (Sigma-Aldrich, I-2018 USA), and a secondary peroxidase conjugated goat 
anti-mouse IgG antibody (Sigma, Mouse Extra-2); then revealed with solution of 0.3 mg/ml of 
3,3’Diaminobenzidine (Sigma, D5905) in presence of 0.2 µl/ml of H2O2 under microscopic 
control, counterstained with Harris´s haematoxylin. 
The insulin-positive areas were measured using a microscope equipped with a digital camera 
and the image analysis Image J. Those who performed the measurements were not aware of 
which experimental group the samples belonged. β-Cell mass was measured as an insulin-
positive area/total pancreatic area ratio by the total pancreas weight, and it was expressed in 
mg. 
Apoptosis Assays: 
To determine -cell apoptosis, 10 m tissue sections from the pancreas were mounted on 
microscope slides and rehydrated through graded ethanol to PBS. The Dead End Fluorometric 
Terminal Deoxinucleotidil-Transferase-mediated 2´-deoxyuridine 5´-Triphosphate nick end 
Labelling (TUNEL) system (Promega, USA) were used according to the manufacturer 
instructions. Insulin was simultaneously counterstained using polyclonal mouse anti-insulin 
antibody (Sigma-Aldrich, USA) incubated overnight at 4ºC; and then stained with a secondary 
anti-mouse IgG antibody (Alexa 546) conjugated (Molecular Probes Inc. Eugene, USA). To 
determine the apoptotic fraction, TUNEL+/Insulin+ cells and islet areas were quantified by 20 
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islets/per sample. We used an image analysis Cell D software (Olympus, Hamburg, Germany). 
Results were noted under randomized conditions by a single investigator and expressed as the 
number of TUNEL+/insulin+ cells/mm2 of islet.  
Proliferation Assays: 
Proliferation was assessed by double immunostaining, using polyclonal rabbit anti-Ki67 (Ab-
Cam, AB16667, UK) and monoclonal mouse anti-insulin (Sigma-Aldrich, I-2018 USA) 
antibodies, according to the manufacturer instructions. Previously, sections from the pancreas 
were incubated for 30 min with 0.1% Triton x-100 in PBS for tissue permeabilization, washed 
with PBS, and then incubated for 30 min with 4% BSA blocking solution in PBS at room 
temperature. Sections were stained using anti-rabbit IgG Alexa 488 and anti-mouse IgG Alexa 
546 conjugated antibodies (Molecular Probes Inc Eugene, USA). The proliferation ratio was 
quantified in 40 islets/per sample. The results were expressed as the number of Ki67+/Insulin+ 
cells/mm2 per area of pancreatic islets. We used the image analysis Cell D software (Olympus, 
Hamburg, Germany). 
Neogenesis study: 
To study PDX-1 expression, as neogenesis marker, the pancreas sections were obtained as 
described above from rats at 3 months-old after surgical intervention. We retrieved sections 
for 10 min with heat in citrate buffer pH 6.7 solution, stained with monoclonal rabbit anti-
PDX-1 antibody (Ab-Cam, 47267 UK) and labelled using biotin conjugated anti-rabbit IgG 
antibody (Sigma-Aldrich, B8895, USA) and revealed with a solution of 0.3 mg/ml of 
3,3’Diaminobenzine (Sigma, D5905) under microscopic control and counterstained with 
Harris´s haematoxylin. The results were observed qualitatively in 12 pancreas areas/per 
animal group.  
Statistical Analysis 
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Measurement data were expressed as mean+SEM. The data were analysed with the Mann 
Whitney-U test, and p<0.05 was considered statistically significant. All statistical analyses 








Weight measurement and food intake 
Body weight gain in rats was monitored from surgery to the time of sacrifice as described in 
methods. No differences appeared between RYGB, Sham and FC (FIG 1A). But there are 
differences between IR50 group and the Sham and FC groups (p<0.05) from the tenth week 
after surgical to sacrifice (Fig 1B). There are also significant differences between the SG group 
and the Sham and FC groups (p<0.01) from surgery to time of sacrifice. In the case of food 
intake, the graphs showed a lower intake in the SG group in relation to Sham and FC groups 
(p<0.05) (Fig 1F) but not in RYBG or IR50 groups (Fig 1D and Fig 1E). 
Otherwise, no changes were observed in the basal glycaemia during the period of the study. 
These data had no significant differences between groups.  
Intra-peritoneal glucose tolerance test (IPGTT) 
An intra-peritoneal glucose tolerance test (IPGTT) was performed in each group every four 
weeks from surgery to sacrifice. No differences appeared between the geometries of the 
curves along the study in RYGB and SG groups (Fig 2A and Fig 2E) versus the control groups. 
But there were significant differences among the curves for the first month, for the second 
(p<0.01) month and third (p<0.05) month in IR50 group (Fig 2C).  
We did not find any difference in the area under the curve (AUC) between the SG and Sham 
and FC groups during the study (Fig 2F). However, in the RYGB group there were important 
differences (p<0.01) in AUC values (+ 15 mg dL/min) respect to the FC group AUC values (+10 
mg dL min-1) at eight weeks (Fig 2B). Differences were also found among the FC group and 
IR50 group AUC values for the second month (+15 mg dLmin-1 versus +19 mg dL/min) (p<0.05) 
(Fig 2D). Finally, differences also persisted in the third month between the IR50 group AUC 
Bariatric surgery and -cell 
12 
 
values (+15 mg dL min-1) and the FC group AUC values (10 mg dL min-1) (p<0.01); but also 
between the IR50 group AUC values and the Sham (10 mg dL/min) (p<0.05) (Fig 2D). 
cell mass 
Pancreatic -cell mass quantification was accomplished for each group immediately after 
sacrifice. Three months following surgery, no cell mass significant differences appeared 
among the RYGB or SG groups versus the Sham and FC groups (Fig 3). On the other hand, there 
were significant differences among the FC and the Sham control (p<0.05) cell mass values 
(+5 mg and +6 mg, respectively) versus the IR50 group cell mass value (Fig 3). 
Proliferation assays  
Thecell proliferation was analysed through the presence of the Ki67 proliferation marker 
in the cell nucleus. The data showed high rates of replication in the IR50 (showed +9 Ki67 
positive cells/mm2 insulin positive area), and the RYGB (presented +11 Ki67 positive cells/mm2 
insulin positive area) over control groups (p<0.05) (Fig 4). The SG group proliferation rates 
were decreased (+5 Ki67 positive cells/mm2 insulin positive area) when compared to the Sham 
and FC group (+8 and +7 Ki67 positive -cells/mm2 insulin positive area, respectively) (p<0.05) 
(Fig 4). 
Apoptosis Assay 
Rate of cell apoptosis was performed using the TUNEL system in each group. No significant 
differences appeared among any of the surgical groups versus Sham or FC groups. 
PDX-1 Analysis 
Presence of new cells from non cells, known as differentiation, was assessed using PDX-
1 transcription factor immunostaining in pancreas samples for each group. The study showed 
that any group expressed variations in the immunostained expression of PDX-1 (Figs 6A and 
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6B) except in the RYGB group, where visually greater intensity and frequency immunostaining 
appeared as we can see in Fig 6C. 
 
  




The endocrine pancreas has a significant remodelling capacity, attending not only to several 
physiological conditions, but also to pathological status such as obesity. Even, this mechanism 
prevents the development of T2DM in many patients 9, 29. The changes in -cell number and 
size, islet neogenesis, proliferation and apoptosis contribute to the remodelling of the 
endocrine pancreas. The balance among these cellular mechanisms determine the change in 
-cell mass. 
Therefore, the study of -cell mass dynamic plays an important role in the adaptation to 
obesity, as well as in the pathogenesis of T2DM. Many studies had focused on bariatric surgery 
effect on pathologic models of T2DM and obesity. Rather than following this model, our 
experiments were designed to analyse the effect of bariatric surgery on glucose control and 
-cell population behaviour in a non-obese and non-diabetic model. We promoted an altered 
transit of aliment across the digestive tube. The pancreas were not affected at the beginning 
of the study, and -cell islets were able to accommodate to the special situation generated 
for the bariatric surgery. Then, the changes in the islets were observed on the basis of a 
healthy pancreas.  
It is well known the hyperglycaemia toxic effect on glucose-sensing of -cell, as occur in 
obesity and T2DM, that lately potentiate -cell dysfunction. So, we considered that the 
histological consequences observed and described in this paper could be diminished because 
these pancreases were able to stabilise the glucose homeostasis. These pancreas of healthy 
rats were not previously damaged for the mentioned factors, without the demand of workload 
on the -cell population. The glycemic parameters showed a resultant equilibrium, which 
represented the histological changes reported in this paper. 
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To the best of our knowledge, not many previous studies have focused on the changes in 
pancreas islets related to surgical models, in order to valuate parameters about the -cell 
mass and the cellular turnover 30.  We report how these processes could be related to the 
maintenance of glucose homeostasis. 
Firstly, the results related to the weight gaining and food intake showed that surgical 
processes reproduced those applied in the human clinic. The functional parameters were 
according to the expected alteration of digestive tube and the increased transit and 
absorption of nutrients. The animals of surgical groups tolerated the surgery; all surgical 
groups gained less weight and food intake was reduced in models that affected the stomach. 
On the other hand, the basal glycaemias were not altered in all of the studied groups. So, we 
consider that the altered flow of feed, or the swift absorption of nutrients were not enough 
stimuli to unbalance the homeostasis. These must be related to the condition of the healthy 
animals, with healthy endocrine pancreases, which were able to adapt to the surgical 
conditions. 
In our study, the different surgeries had various consequences on glucose tolerance. Through 
the study of the IPTTG test, the results showed significant differences between FC group 
versus IR50 and RYGB groups in some intervals of the study (Fig 2). One common point in the 
IR50 and RYGB surgical groups was that both groups produced a shortening of food transit in 
the small intestine (specifically by the jejunum), unlike in the SG group. These new anatomical 
situations, according to our data, seemed to cause a modification in their AUC. This effect 
could probably be due to the early arrival of food to the ileum. It is well known that the rapid 
influx of nutrients may trigger the release of several incretins (as GLP-1, GIP, Oxyntomodulin, 
PYY, etc.) and this would lead to a normalization of the AUC in both groups 11, 16, 31. In this 
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sense, the AUC is marking the global capacity of the endocrine pancreas to resolve the glucose 
overload.  
In addition, we could see a normalization of the AUC in the RYGB group from the eighth week. 
However, this normalization of the AUC did not occur in the IR50 group. This different 
behaviour in the IR50 group could be explained by the decreased transit of food through the 
duodenum, which results in less secretion of GIP by K-cells 3, 32. This idea was the etiological 
basis of the foregut hypothesis. It argued that RYGB, and partially RI50, bypasses the foregut, 
so it was inhibited the -cell function, influenced by the GIP, originating from the duodenum 
and proximal jejunum 22. These results could reinforce the role of the ileum. 
We explored the effect of these bariatric surgeries on the pancreas because we considered 
that islets must be the target of the entero-insular axis.  We believe that the improved of 
cell dysfunction must be related to changes in the cellularity of islets, and this could be a 
consequence of the surgically altered anatomy of the gastrointestinal system.  
Even, some authors had reported that the surgery per se cause an inflammatory distress, 
which impair insulin sensitivity. This metabolic stress related to surgery could explain why our 
Sham control presented different parameters than FC. We reported results which Sham group 
presented significant differences with surgical groups, meanwhile did not occurred with FC 33. 
First, we showed that cell mass was slightly increased in the surgical groups following 
surgery, but only the IR50 group presented with significant differences versus the FC and the 
Sham groups (Fig 3B). These effects could be explained by increased stimulation of the ileum 
due to earlier presence of food, which could lead to an elevated release of GLP-1 or PYY 11, 18, 
31. This idea could be supported for the data of RYGB group. The behaviour of the AUC and the 
light increase of -cell mass in the RYGB group indicated a common aspect with RI50. Both 
groups, RYGB and RI50 (malabsorptive and mixed surgical groups) incited an early arrival of 
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nutrients to the ileum. However, this mechanism was occurred sooner in the IR50 when 
compared to the RYGB group, so the effect was greater and earlier in the IR50 group. Both 
groups, IR50 and RYGB, had significant proliferation rates respect to the controls groups (Fig 
4), which correlate with -cell mass changes. 
The possible role of GLP-1 is controversial. The proliferative effect of the release of GLP-1 on 
cell population had well described 34, 35, 36, 37. But some authors considered that GLP-1 has 
not a direct effect on the pancreas, and it is related to satiety by acting at central nervous 
system 38. Otherwise, the GLP-1 receptor modifications have been excluded as related to the 
T2DM improvement after SG 39. 
The SG group showed a significant low proliferation ratio respect to the controls (Fig 4), but 
did not show a decreased -cell mass respect to the controls (Fig 3). The explanation of this 
could be a slight decrease in the cell apoptosis ratio in SG group. However, no significant 
differences in the cell apoptosis rates appeared between any studied groups (Fig 5). Thus, 
the explanation for this effect must be an increased phenomenon of cell differentiation from 
stem cell to cell 40. This fact was supported by the normal presence of PDX-1 stained -cells, 
as observed in SG samples (Figure 6). 
Regarding the PDX-1 study parameters, the cell differentiation from stem cell to cell 40, 41 
after bariatric surgery, showed more data in the other surgical groups. In the RYGB samples, 
we observed an increased presence of PDX-1 -cell (Figure 6C). The increased -cell 
differentiation is related to some stimulating factors (e.g. GLP-1 or PYY) on the pancreas 18, 19, 
20.  
We note that both surgical techniques (RYBG and RI50) have a common region, which is 
affected –the duodenum and first jejunal portion-, and this increment could be related to a 
direct influence to the pancreas. But, in a contrary sense, the exclusion of duodenum to the 
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nutrients in the RYGB versus the RI50 could explain the different effect of both techniques on 
the pancreas. We think that the so called anti-incretin effect, secreted in the duodenum (e. g. 
CCK or GIP) could be in the basis of this differences 16, 21, 22. 
The complete observation of data leads us to suggest the presence of two possible 
mechanisms that could be in the basis of the -cell mass increase. The first proposed 
mechanism is the direct path due to the early presence of food in ileum, as is the case of the 
IR50 and RYGB surgeries. The premature appearance of partially digested nutrients in the 
ileum seemed to show an earlier increase in proliferation. The proliferation mechanism could 
be related to ghrelin level changes 14, 42. This direct pathway could too act on cell mass 
through a release of GLP-1, a recognized stimulatory of -cell proliferation agent secreted by 
L-cells 4, 10, 34, 35. We consider that the entero-hormonal axis must be the effector of the final 
changes in the cellular conformation of endocrine pancreas. 
A second path could be related to the restriction of the transit of food through the jejunum. 
The mechanism appeared too in the IR50 and RYGB surgical groups. This second mechanism 
would act indirectly through a transient modification of glucose tolerance. The surgical 
processes that induce a reduction of glucose tolerance could stimulate an increase in -cell-
mass, due to the high blood glucose level 43, 44. But in the case of the IR50 group, this 
mechanism seems to be more important than in the RYGB group (Fig 2). This is related to the 
fact that the IR50 samples experienced a shorter transit through the jejunum than in the RYGB 
group. Therefore, the second proposed mechanism would reinforce the first path we 
described above, the enhanced growth of -cell mass. 
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Figure 1. Weight gain in groups RYGB (Fig 1A), IR50 (Fig 1B) and SG (Fig 1C) from surgery to 
sacrifice. Significant differences were found between IR50 group (p<0.05) and SG group 
(p<0.01) versus Sham and FC groups. Food intake in RYGB (Fig 1D), IR50 (Fig 1E) and SG (Fig 
1F) versus control groups, for the first month after surgery. No food intake difference in IR50 
and RYGB were reported (Fig 1D and Fig 1E). Significant difference (p<0.05) between food 
intake values for SG group and FC group were seen. The Y-axis in weight gain of IR50 (Fig 1E) 
had a different unit in order to facilitate the depiction. 
Figure 2. IPTTG geometry curves development in surgery groups at the first, second and third 
months (Fig 2A, Fig 2C and Fig 2E) and area under curve (AUC) in surgical, sham and fasting 
control groups, expressed as mg/dL/min-1 (Fig 2B, Fig 2D and Fig 2F). Important differences 
appeared in IPTTG curves in the IR50 group between first and the second months (p<0.01) and 
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first and the third months (p<0.05) (Fig 2C). Also, significant differences were seen in the AUC 
at the second month between the IR50 surgery and fasting control group (p<0.05) and 
between the IR50 surgery and sham group (p<0.05) and the IR50 surgery and fasting control 
group at the third month (p<0.01) (Fig 2D). There were no differences in IPTTG curve 
development in RYGB and SG groups (Fig 2A and Fig 2E). However, significant differences were 
seen in the AUC between the RYGB and fasting control groups at the second month (p<0.05) 
(Fig2B). The Y-axis in the IPTTG and the AUC of SG (Fig 2E and 2F) had a different unit in order 
to facilitate the depiction. 
Figure 3. cell mass quantification expressed as mg. The difference appeared in this study 
between Sham control group and IR50 group, with the IR50 group cell mass having roughly 
0.6 times more cell mass (p<0.05) compared to the Sham control group.  
Figure 4. Proliferation assays. Rates of –cell proliferation expressed as the number of cells, 
which expressed Ki67 positive/ insulin positive area (mm2). IR50 and RYGB groups show higher 
proliferation rates than Sham control group (p<0.05). However, the rate of cell proliferation 
appeared diminished in SG group, compared to Sham control (p<0.05). 
Figure 5. Apoptosis assays. Rates of –cell apoptosis expressed as the number of TUNEL 
positive -cells/ insulin positive area (mm2) for all of the groups. No one group showed 
differences in -cell apoptosis ratio between surgical groups and controls. 
Figure 6. Images showing pancreas expression of PDX-1. Fasting control group (6A), Sham 
control group (6B) and RYGB group (6C). Enhanced expression of PDX-1 appeared in the RYGB 
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